135 related articles for article (PubMed ID: 17897022)
1. DNA topoisomerase II structures and anthracycline activity: insights into ternary complex formation.
Dal Ben D; Palumbo M; Zagotto G; Capranico G; Moro S
Curr Pharm Des; 2007; 13(27):2766-80. PubMed ID: 17897022
[TBL] [Abstract][Full Text] [Related]
2. Interaction model for anthracycline activity against DNA topoisomerase II.
Moro S; Beretta GL; Dal Ben D; Nitiss J; Palumbo M; Capranico G
Biochemistry; 2004 Jun; 43(23):7503-13. PubMed ID: 15182192
[TBL] [Abstract][Full Text] [Related]
3. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Atwal M; Swan RL; Rowe C; Lee KC; Lee DC; Armstrong L; Cowell IG; Austin CA
Mol Pharmacol; 2019 Oct; 96(4):475-484. PubMed ID: 31399497
[TBL] [Abstract][Full Text] [Related]
4. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
5. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines.
Binaschi M; Farinosi R; Borgnetto ME; Capranico G
Cancer Res; 2000 Jul; 60(14):3770-6. PubMed ID: 10919649
[TBL] [Abstract][Full Text] [Related]
6. A flow cytometry-based method for a high-throughput analysis of drug-stabilized topoisomerase II cleavage complexes in human cells.
de Campos-Nebel M; Palmitelli M; González-Cid M
Cytometry A; 2016 Sep; 89(9):852-60. PubMed ID: 27517472
[TBL] [Abstract][Full Text] [Related]
7. [Molecular determinants of response to topoisomerase II inhibitors].
Lansiaux A; Pourquier P
Bull Cancer; 2011 Nov; 98(11):1299-310. PubMed ID: 22023806
[TBL] [Abstract][Full Text] [Related]
8. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.
Marinello J; Delcuratolo M; Capranico G
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404148
[TBL] [Abstract][Full Text] [Related]
9. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Tavian D; Silvestrini A
Curr Med Chem; 2017; 24(15):1607-1626. PubMed ID: 27978799
[TBL] [Abstract][Full Text] [Related]
10. On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs.
Wu CC; Li YC; Wang YR; Li TK; Chan NL
Nucleic Acids Res; 2013 Dec; 41(22):10630-40. PubMed ID: 24038465
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
12. Bioassays and In Silico Methods in the Identification of Human DNA Topoisomerase IIα Inhibitors.
Bergant K; Janezic M; Perdih A
Curr Med Chem; 2018; 25(28):3286-3318. PubMed ID: 29508675
[TBL] [Abstract][Full Text] [Related]
13. DNA topoisomerase II as the primary target of anti-tumor anthracyclines.
Zunino F; Capranico G
Anticancer Drug Des; 1990 Nov; 5(4):307-17. PubMed ID: 1963303
[TBL] [Abstract][Full Text] [Related]
14. Eukaryotic DNA topoisomerases mediated DNA cleavage induced by a new inhibitor: NSC 665517.
Gupta M; Abdel-Megeed M; Hoki Y; Kohlhagen G; Paull K; Pommier Y
Mol Pharmacol; 1995 Oct; 48(4):658-65. PubMed ID: 7476891
[TBL] [Abstract][Full Text] [Related]
15. Identification of yeast DNA topoisomerase II mutants resistant to the antitumor drug doxorubicin: implications for the mechanisms of doxorubicin action and cytotoxicity.
Patel S; Sprung AU; Keller BA; Heaton VJ; Fisher LM
Mol Pharmacol; 1997 Oct; 52(4):658-66. PubMed ID: 9380029
[TBL] [Abstract][Full Text] [Related]
16. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
[TBL] [Abstract][Full Text] [Related]
17. Single-molecule Förster resonance energy transfer (FRET) analysis discloses the dynamics of the DNA-topoisomerase II (Top2) interaction in the presence of TOP2-targeting agents.
Huang WC; Lee CY; Hsieh TS
J Biol Chem; 2017 Jul; 292(30):12589-12598. PubMed ID: 28630044
[TBL] [Abstract][Full Text] [Related]
18. Increasing the distance between two monomers of topoisomerase IIβ under the action of antitumor agent 4β-sulfur-(benzimidazole) 4'-demethylepipodophyllotoxin.
Sun LY; Zhu LW; Tang YJ
Sci Rep; 2018 Oct; 8(1):14949. PubMed ID: 30297860
[TBL] [Abstract][Full Text] [Related]
19. Antitumor AZA-anthrapyrazoles: biophysical and biochemical studies on 8- and 9-aza regioisomers.
Sissi C; Leo E; Moro S; Capranico G; Mancia A; Menta E; Krapcho AP; Palumbo M
Biochem Pharmacol; 2004 Feb; 67(4):631-42. PubMed ID: 14757163
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced conformational population shifts in topoisomerase-DNA ternary complexes.
Huang NL; Lin JH
Molecules; 2014 Jun; 19(6):7415-28. PubMed ID: 24905608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
